The estrogen receptor (ER), like other members of the nuclear receptor superfamily, possesses two separate transcriptional activation functions, AF-1 and AF-2. Although a variety of coactivators and corepressors of AF-2 have been identified, less is known of the mechanism of action of AF-1. We have used the yeast two-hybrid system to isolate a cDNA coding for a protein that binds specifically to the AF-1 region of human ERA. This cDNA codes for the transcription factor basal transcription factor 3 (BTF3). The specificity of the interaction between BTF3 and ERA has been confirmed in vivo and in vitro. Transient transfection experiments reveal that overexpression of BTF3 modulates the transcriptional response of reporter genes to ERA. BTF3 interacts with ERA that has been activated either by 17B-estradiol (ligand-dependent activation) or by epidermal growth factor (ligand-independent activation). The effects of BTF3 on the reporter genes requires the presence of ERA containing an active AF-1 function. BTF3 may be a component of the mechanism by which the AF-1 function of ERA stimulates gene transcription.
Introduction
Steroid hormones, such as 17h-estradiol, produce responses in their target cells by regulating gene expression (1, 2) . The receptors for steroid hormones belong to a superfamily of nuclear receptors that, upon binding their individual ligand, are able to bind to specific DNA sequences, hormone response elements, and stimulate the initiation of transcription of nearby hormone-responsive genes (3, 4) . Members of the receptor superfamily contain two separate regions that are involved in the activation of transcription (4, 5) . These two transactivation functions (AF-1 and AF-2), which are physically distinct from each other, show differences in their mode of action. In particular, the activity of AF-2 is dependent on ligand binding by the receptor, whereas AF-1 activity is ligand-independent (6, 7). More recently, it has been shown that non -ligand signal molecules such as certain growth factors (8) (9) (10) (11) (12) (13) (14) may regulate AF-1 activity. The mechanism by which the receptor, bound to its response element, may influence the assembly/stability of the multiprotein transcription initiation complex, situated at the gene promoter, is unclear. Transcriptional interference (''squelching'') experiments have provided evidence that both AF-1 and AF-2 require coregulator molecules to achieve stimulation of transcription (15, 16) . Subsequently, a variety of molecular candidates for AF-2 coregulators, both coactivators and cosuppressors, have been described (17) (18) (19) (20) (21) . Such coregulator proteins bind in a ligand-dependent manner to regions of the amino acid sequence that are conserved between receptors. Various mechanisms have been suggested by which they may contribute to transcriptional activation (22, 23) .
The mechanism of action of the AF-1 transactivation function is more obscure, not least because of the lack of sequence conservation at the amino-terminal end of nuclear receptors, where AF-1 is located. Fewer coregulator proteins for AF-1 have been described (11) (12) (13) (14) , although it has recently been reported that the steroid receptor RNA activator molecule acts as an AF-1 coactivator (21) , and that certain AF-2 coactivators may also bind to the A/B domain of estrogen receptor a (ERa; refs. 24, 25) . ER AF-1 binds the COOH terminus of glucocorticoid receptor -interacting protein 1 (NID/AF-1) and other p160s (24) . ERa AF-1 transcriptional activity is also enhanced by p300 and DEAD box protein p68/p72, which form a protein complex with p160 family proteins and p300/CBP, and directly bind to the A/B domain to potentiate AF-1 activity (11, 26) . The phosphorylation of the serine residue at position 118 in the A/B domain stabilizes the complex formation of ER and the coactivator complex containing p68/p72 to potentiate the AF-1 activity (19, 26) . Phosphorylation of certain serine residues, within the A/B domain of several nuclear receptors, may play an essential role in the action of AF-1 (10, 26, 27) . It has been shown that a point mutation that replaces Ser 118 of human ERa with an unphosphorylatable Ala residue prevents the activation of the receptor by epidermal growth factor (EGF; refs. 10, 26) .
We have therefore used the yeast two-hybrid system (28) to isolate cDNA coding for a protein that binds specifically to the region of the human ER that contains the AF-1 transactivating function. This cDNA encodes a previously identified transcription factor which is a 27 kDa protein, the precise function of which is unclear (29) . In human cells, alternative splicing of the initial transcript of the basal transcription factor 3 (BTF3) gene seems to give rise to mRNAs coding for two versions of the protein, one (BTF3a) encoding the full-length protein (206 amino acids), the other (BTF3b) lacking the first 44 amino acids (29) . Our cDNA represents a previously reported (29) version of BTF3b mRNA that possesses a different 5 ¶ untranslated sequence from that originally described. Transient transfection experiments showed the functional significance of the association of BTF3 with the ER.
Results

Isolation of cDNA Coding for a Protein that Binds to the A/B Domain of the ERa
A commercial yeast two-hybrid system (see Experimental Procedures) was used to identify human cDNA coding for proteins that bind to the A/B domain (containing the AF-1 function) of the human ERa. A cDNA library constructed from EGF-stimulated MCF-7 human breast cancer cells was inserted into the ''target'' vector whereas cDNA coding for amino acids 1 to 185 (the complete A/B domain) of human ERa was inserted into the ''bait'' vector. The two recombinant vectors were coexpressed in yeast cells and f10
9 yeast transformants were screened. Four hundred yeast cells were selected on the basis of their ability to grow in medium lacking histidine, i.e., demonstrating activation of the HIS3 reporter gene. These were further screened for their ability to express a second reporter gene, lacZ, and six positive clones were identified.
Characterization of the Isolated cDNA
The DNA sequences of the inserts in three of the clones (f1, f2, and b3) were determined and found to contain the same sequence (875 bp in length). A BLAST search of the GenBank nucleotide database revealed that this sequence was 99% identical to a previously reported variant of the BTF3b transcription factor (29) . When clone f1 DNA was hybridized to a Northern blot of total RNA from the estrogen-responsive human breast cancer cell line, MCF-7, it produced a single band of the expected size (f0.9 kb) for BTF3 mRNA (Fig. 1) . Control (1-fold induction) and estradiol (4.2-fold induction) cells were tested. High expression of BTF3 was also observed in cells treated with EGF (3.9-fold induction). The specificity of the binding of BTF3b to the A/B domain of ERa was determined by returning the f1 plasmid to yeast cells in the presence of a series of bait vectors containing cDNAs coding for alternative protein fragments ( Fig. 2A) . Expression of the lacZ reporter gene occurred only in yeast cells containing the BTF3 plasmid in the simultaneous presence of an A/B domaincontaining bait plasmid. Significantly, although binding was evident between BTF3b and full-length ERa, no binding was seen with receptor lacking the A/B domain (domains C/D/E/F, amino acids 179-595). These data indicate that BTF3b binds specifically to the region of the ER containing the AF-1 function.
We confirmed and extended these results by examining the specificity of BTF3b binding using an alternative version of the two-hybrid system in mammalian cells. Figure 2B presents the results of BTF3b-binding experiments in MCF-7 cells. Similar results were obtained with HeLa cells (data not presented). Activation of the reporter gene was only detected when BTF3 was coexpressed with the A/B domain of ERa. Interestingly, no binding could be detected between BTF3b and the A/B domain of ERh. In a pilot study, we have shown no binding between BTF3 and vitamin D receptor (VDR), retinoid X receptor, peroxisome proliferator-activated receptor, glucocorticoid receptor (GR), and androgen receptor (AR) (data not shown). It should be noted that when transfected without BTF3, the A/B domain of ERa, but not of ERh, caused a small but consistent increase in reporter gene activity.
Binding between BTF3b and the A/B domain of ERa was also shown in vitro (Fig. 3A) . MCF-7 cells were separately transfected with either the BTF3b-containing target plasmid or a target plasmid containing the BTF3b sequence inserted in the antisense orientation or an expression plasmid encoding fulllength ERa. Whole-cell extracts prepared from the transfected MCF-7 cells were mixed and incubated in the presence of an antibody against BTF3 (Santa Cruz Biotechnology, Inc.). The immunoprecipitated proteins were separated by PAGE and subjected to Western blotting using a monoclonal antibody against human ERa (Fig. 3A, top) . Immunoprecipitate was analyzed by Western blot using BTF3 antibody as a control (Fig. 3A, bottom) . This data clearly shows that ERa is specifically coimmunoprecipitated with BTF3b. In this experiment, we did not observe coimmunoprecipitation of the endogenous ERa from MCF-7 cells when using the BTF3 antibody. This is probably due to the association of unliganded ERa with HSPs and the requirement for estradiol to dissociation of this complex and stabilization of the receptor. In agreement with this, we showed that the binding in vivo was enhanced by the ligand (Fig. 3C) .
To investigate whether BTF3a and ERa could interact directly, coimmunoprecipitation experiments were done in cell-free protein-synthesizing reticulocyte lysates. Control lysates contained either ERa (Fig. 3B, lane 1) or 35 S-BTF3 (Fig. 3B, lane 2) and produced proteins of the correct size. À8 mol/L) or EGF (100 ng/mL), for a further 24 h. Total RNA was isolated from the cells and subjected to Northern blot analysis. After hybridization with probes for BTF3 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH ), each autoradiograph was quantified by densitometry. BTF3 results were normalized relative to the glyceraldehyde-3-phosphate dehydrogenase signals and are expressed as fold increase above the control cell result. A representative Northern blot illustrating the induction of BTF3 mRNAs by estradiol (E) and EGF compared with mRNA levels in untreated cells (C ). 35 S-BTF3a -containing lysates were incubated with nonradioactive ERa-containing or unprogrammed lysates. The resultant protein interaction complexes were immunoprecipitated with anti-ERa antibody (30) and analyzed on polyacrylamide gels (Fig. 3B ). An antibody to ERa coimmunoprecipitated a 35 S-labeled protein of 27 kDa from BTF3a-producing lysates (Fig. 3B, lane 3) . These 35 S-27 kDa proteins corresponded to the major radioactive protein in the lysates and possessed the same molecular weight as reported for human BTF3a (31) . The specificity of the immunoprecipitated complexes formed between BTF3a and ERa was tested as follows. When 35 Slabeled BTF3a-containing lysates were incubated with unprogrammed nonradioactive lysates and then immunoprecipitated with anti-ERa, no radioactive BTF3a protein of 27 kDa was observed on the resultant polyacrylamide gels (Fig. 3B, lane 4) . This radioactive band was not observed in controls in which an unrelated transcription factor Tip 60-HA (ref. 32 ; Fig. 3B , lane 5) or unprogrammed lysates-hemagglutinin (Fig. 3B , lane 6) replaced those containing ERa. Immunoprecipitate was analyzed by Western blot using ERa and hemagglutinin antibodies as controls (Fig. 3B, bottom) .
To determine whether interaction occurred between endogenous ERa and endogenous BTF3 in untransfected MCF-7 cells, cell lysates were immunoprecipitated with control IgG or ERa antibody, followed by Western blotting of the precipitates with antibodies to ERa and to BTF3 as indicated. A strong interaction between endogenous ERa and BTF3 was observed in both estradiol-treated and untreated MCF-7 samples (Fig. 3C ). This interaction was dependent on the presence of ERa in the complex, without it, no interaction occurred (Fig. 3C) . The association between ERa and BTF3 was significantly enhanced by the presence of estradiol, whereas the presence of an antiestrogen, such as ICI 164384 was observed to abrogate this interaction (data not shown). These results confirm that endogenous ERa and BTF3 could form interacting complexes in untransfected MCF-7 cells.
Modulation of ER Function by BTF3
The functional significance of the binding of BTF3 to the ER was investigated in transient transfection experiments. The cDNA encoding BTF3b or the active form BTF3a were cloned into the mammalian expression vector pBK-CMV. We cotransfected MCF-7 cells with ERE.VIT.CAT, an estrogeninducible reporter construct (33) and HEG0, which encodes the wild-type human ERa (34) , in the presence of a range of amounts of the BTF3b or BTF3a expression vector. CAT activity was measured after 48 h of exposure of the transfected cells to estradiol or EGF (Fig. 4A and B) . The overexpression of BTF3b (Fig. 4A) or BTF3a (Fig. 4B ) in MCF-7 cells increased the stimulation of reporter gene transcription by both estradiol and EGF in a dose-dependent manner. Cells transfected with 1 ng/30 mm dish (f1.1 Â 10 5 cells) of the BTF3b or BTF3a plasmid showed 2-and 3.2-fold increases (P = 0.0003 and P = 0.0007, respectively) in estrogen-induced CAT activity and 3-and 7.5-fold increases (P = 0.0008 and P = 0.0002, respectively) in EGF-induced CAT activity. Transfection with larger amounts of BTF3b or BTF3a vector reduced the level of CAT induction. It would therefore seem that the stimulation of transcription by BTF3b or BTF3a requires the presence of ERa that has been activated, by either a ligand-dependent or a ligand-independent mechanism, and is not simply a consequence of an increase in efficiency of the basic transcription machinery.
The Receptor Domain Specificity of the BTF3 Effect on ER Activity in MCF-7 Cells
Transient transfection studies, using two deletion mutants and a point mutant of ERa, were carried out to establish which transactivation functions were affected by the presence of overexpressed BTF3b or BTF3a. HE15 contains an insert coding for a truncated ERa (amino acids 1-282), which lacks the ligand-binding domain and AF-2 but retains AF-1 (6). HEG19 codes for a truncated ERa (amino acids 179-595), which lacks AF-1 but retains ligand-binding and AF-2 (4). HE457 codes for a full-length ER containing a point mutation that substitutes Ala for Ser at residue 118 within the A/B domain (27) . MCF-7 cells were cotransfected with the ERE.VIT.CAT reporter construct, 1 ng of BTF3b (Fig. 5A) or BTF3a (Fig. 5B) plasmid and either wild-type ERa (HEG0) or mutant ERa plasmid, and were then cultured for 24 h in the presence or absence of estradiol ( Fig. 5A and B) . BTF3b (Fig. 5A) or BTF3a (Fig. 5B) , in the presence of wild-type ERa, increased the response of ERE.VIT.CAT to estradiol. In the presence of ERa lacking ligand-binding activity, no response to estradiol was seen and BTF3b or BTF3a were without effect. A receptor lacking AF-1 was able to support a low level of induction by estradiol but was unaffected by BTF3b or BTF3a overexpression. The response of the reporter gene to estradiol, in the presence of HE457 was unaffected by BTF3b or BTF3a overexpression. Apparently, this point mutation in the A/B domain significantly reduces the sensitivity of the ER to BTF3b and BTF3a when activated by estradiol.
These results were compared with those from similar experiments in which the transfected MCF-7 cells were incubated with EGF to achieve ligand-independent activation of ERa (Fig. 5C and D) . In the presence of the wild-type receptor (HEG0), EGF achieved a significant induction (P = 0.003 and P = 0.002, respectively) of ERE.VIT.CAT. This response to EGF was modified by BTF3b (Fig. 5C ) and BTF3a (Fig. 5D ) overexpression in the same manner as the response to estradiol, i.e., BTF3b or BTF3a increased the induction of ERE.VIT.CAT by EGF. EGF activated the ERa primarily by its effect on AF-1 activity (9, 10) and was therefore able to induce reporter gene activity in the presence of the truncated receptor HE15. Overexpression of BTF3b and BTF3a had a positive effect on EGF induction of ERE.VIT.CAT in the presence of HE15. HEG19 encodes a receptor lacking AF-1, which fails to support reporter gene induction by EGF, showed no response to BTF3b or BTF3a overexpression. The point mutation in HE457, which has been reported previously (10, 26) , abolishes ligand-independent activation of the ER by EGF and overexpression of BTF3b or BTF3a failed to restore EGF responsiveness. These results confirm that the effects of BTF3b and BTF3a on reporter gene expression are exerted via AF-1 and indicate that AF-1 needs to be ''activated'' if it is to respond to BTF3 overexpression.
Discussion
The A/B domain has been shown to contain transactivating activity (AF-1) in most, if not all, members of the nuclear receptor superfamily (3, 6) . However, it is also the region of these receptors that shows least conservation in length or sequence (35) . The E domain, which contains the second transactivating function (AF-2) as well as ligand-binding activity, is more tightly conserved and an amphipathic a-helix structure has been identified within the domain that seems to be essential for AF-2 activity (36). Evidence has been presented that AF-1 and AF-2 interact to produce the full transactivating function of the wild-type ER (5, 6, 37), although deletion mutants of the receptor indicate that AF-1 and AF-2 could act independently of each other. AF-2 stimulation of the initiation of transcription is believed to occur by its ligand-dependent recruitment of a multiprotein coactivator complex and a variety of AF-2 coactivators (and corepressors) have been identified (17) (18) (19) (20) (21) . Transcriptional interference (squelching) experiments also indicate that AF-1 acts via coregulators (11-16) but fewer candidates have been identified.
We used the yeast two-hybrid system (28) to isolate a cDNA coding for a protein that binds specifically to the region of the human ER containing the AF-1 transactivation function. Determination of the sequence of the cDNA revealed that it originated from mRNA for the BTF3b transcription factor (29) . No binding of this protein to the remainder of the ER could be detected by the yeast two-hybrid system. This was confirmed using the two-hybrid system in mammalian cells. ERa and ERh have considerable divergence of sequence in their A/B domains and it is therefore interesting that no binding between this region of ERh and BTF3 was detected. Binding of BTF3 to the ER seems to occur in a sequence-specific manner.
BTF3 is a 27 kDa protein whose precise function is unclear. It was originally identified as a basal transcription factor required for the accurate initiation of transcription by RNA polymerase II (31) . However, subsequent studies indicated that BTF3 was not in fact essential for specific, in vitro initiation of transcription (38) . Its biological importance is shown by the fact that mouse embryos, homozygous for a deletion of the BTF3 gene, die at an early stage after implantation (39) . BTF3 is evolutionarily conserved and is present in a variety of mammalian cells (29) . In yeast (Saccharomyces cerevisiae) there are two homologous genes, although yeast BTF3 inhibits the transcription of specific genes in yeast cells (40) . In human cells, alternative splicing of the initial transcript of the BTF3 gene seems to give rise to mRNAs coding for two versions of the protein, one (BTF3a) encoding the full-length protein (206 amino acids), the other (BTF3b) lacking the first 44 amino acids (29) . Our cDNA represents a previously reported (29) version of BTF3b mRNA that possesses a different 5 ¶ untranslated sequence from that originally described.
We investigated the functional role of BTF3b and BTF3a in ER activation of gene transcription by overexpressing the genes in cells cotransfected with ER and estrogen-responsive reporter in estradiol-induced transcription of the ERE.VIT.CAT reporter declines, possibly indicating that the excess BTF3 protein is in some way competing with the ER-bound protein for functional targets. These data suggest that the ER was squelched by high levels of BTF3 and its ability to sequester target proteins required for transcriptional activation by the receptor (41). We observed no inhibitory effect of BTF3 overexpression on MCF-7 cell growth (data not shown). The use of deletion mutants of the ERa confirmed that the BTF3 effect on reporter gene transcription requires the presence of the A/B domain (AF-1) of the ER. In addition, the response to BTF3 (b and a) also requires that the AF-1 exists in an ''activated'' state, either as the result of ligandbinding (HEG0 + estradiol) or as the result of ligandindependent activation (HE15 + EGF). The point mutation (HE457) that converts Ser 118 to an unphosphorylatable Ala reduces but does not prevent the response of estradiolactivated ER to BTF3 overexpression (compare Fig. 5A and B and Fig. 5C and D) . However, this mutation completely eliminates the response of EGF-activated ER to BTF3 (compare Fig. 5A and B and Fig. 5C and D) . It seems that phosphorylation at Ser 118 may be important for productive interaction with BTF3 but that estrogen-binding promotes interaction in an alternative manner.
In summary, we present evidence suggesting the existence of a mechanism by which the AF-1 transactivation function of the human ER may regulate gene transcription. This mechanism involves the BTF3 ''basal'' transcription factor in a new role.
Experimental Procedures
Chemicals and Materials
Tissue culture medium, newborn calf serum, FCS, antibiotics, and trypsin-EDTA were purchased from Life Technologies. 17h-Estradiol and EGF (human, recombinant) were purchased from Sigma. Restriction enzymes, DNA-modifying enzymes, and Taq polymerase were obtained from Boehringer Mannheim.
Expression Vectors and Reporter Constructs
The ERa plasmids and estrogen-responsive reporter constructs were obtained from the laboratories in which they were originally constructed. HEG0 (34) encodes a full-length (amino acids 1-595), wild-type human ERa. HE15 (5) encodes amino acids 1 to 282 and HEG19 (34) encodes amino acids 179 to 595 of the human ERa. HE457 (27) encodes a fulllength human ERa containing a point mutation that replaces Ser 118 by an alanine residue. ERE.VIT.CAT contains a promoter that is derived from the Xenopus laevis vitellogenin B1 gene (33) .
Yeast hybrid-protein expression vectors, pBDGAL4 and pADGAL4, were obtained from Stratagene as components of the HybriZAP kit. The pBK-CMV mammalian expression vector was obtained from Stratagene and the pSV-hgalactosidase plasmid was obtained from Promega. Mammalian hybrid-protein expression vectors, pM and pVP16, together with the reporter gene vector, pG5CAT, were obtained as part of the Mammalian MATCHMAKER kit (Clontech Laboratories).
Construction and Screening of the cDNA Library
The HybriZAP two-hybrid system (Stratagene) was used, according to the manufacturer's instructions, to screen a cDNA library constructed from polyA + RNA isolated from MCF-7 cells. The cells had been depleted of steroids, transferred to serum-free medium, and then cultured for 24 h in the presence of EGF, as previously described (10) . The cDNA was directionally inserted into EcoRI/XhoI-digested pADGAL4 vector. Human ERa A/B domain DNA (coding for amino acids 1-185) was prepared by PCR amplification from plasmid HEG0 DNA. The A/B DNA was inserted into the EcoRI site of the pBDGAL4 vector and the correct orientation and insertion of the DNA was confirmed by determining the nucleotide sequence of the recombinant vector across the EcoRI site. After cotransformation of yeast YRG-2 cells with the two vectors, cells were selected for growth in medium lacking histidine (activation of HIS-3 reporter gene, indicating cDNA-encoded protein binding to the hybrid ''bait'' protein). From f10 9 transformed yeast cells, 400 cells were selected in this manner. These were then assayed for their expression of the hgalactosidase reporter gene by filter lift assay-the production of blue coloration with X-gal substrate indicating a positive result. Six yeast clones expressing h-galactosidase were identified.
Isolation and Sequencing of cDNA Clones
For the cloning of BTF3a, total RNA was isolated from HeLa cells using the guanidine isothiocyanate/acid phenol method (42) and used to synthesize the cDNA using avian myeloblastosis virus reverse transcriptase (43) . An aliquot of cDNA was amplified by PCR using the primers oligonucleotide, forward: 5 ¶ATGCGACGGACAGGCGCA3 ¶ and reverse: 5 ¶TCAGTTTGCCTCATTCTT3 ¶, derived from BTF3a genes. The PCR incubations were carried out for 36 cycles of denaturation (94jC for 1 min), annealing (46jC for 1 min), and elongation (72jC for 2 min) using a reaction mixture containing 500 pmol of each oligonucleotide, 200 Amol/L of deoxynucleotide triphosphate, and a reaction buffer provided with the Taq DNA polymerase (Hoffmann-La Roche). PCR products were isolated from agarose gel and cloned directly into the pBK-CMV expression vector (Stratagene) following the manufacturer's instructions. After transformation, a limited number of positive clones were selected and sequenced to identify the PCR products corresponding to BTF3a fragments.
Determination of Binding Specificity In vivo
The p53 (DNA coding for amino acids 72-390 of murine p53 within pBDGAL4 vector), pLamin C (DNA coding for amino acids 67-230 of human lamin C within pBDGAL4), and pSV40 (DNA coding for amino acids 84-708 of the SV40 large T-antigen within pADGAL4 vector) control plasmids were obtained from Stratagene as components of the HybriZAP yeast two-hybrid kit. The ER coding DNA was released from HEG19 plasmid by EcoRI digestion and then ligated with pBDGAL4 vector to create the ''domains C/D/E/F'' bait plasmid. The quantitative liquid h-galactosidase assay was conducted according to protocol 10 of Olesen et al. (44) .
The positive control plasmids, pM-53 (a fusion of GAL4 DNA binding domain to murine p53) and pVP16-T (a fusion of GAL4 activating domain to SV40 large T antigen, which interacts with p53) were components of the Mammalian MATCHMAKER two-hybrid kit. DNA coding for the complete A/B domain (amino acids 1-185) of ERa was amplified by PCR of HEG0 using primers that incorporated EcoRI (5 ¶ primer) or SalI (3 ¶ primer) sites. The amplified product was digested with EcoRI and SalI and ligated to plasmid pM, digested with the same restriction enzymes. In the same manner, the sequence coding for full-length BTF3b was amplified by PCR of plasmid pAD-GAL4 f1 and inserted into EcoRI/SalI digested pVP16. The complete coding sequence of HEG19 was released by digestion with EcoRI and SalI and then ligated to the pM vector, digested with the same enzymes. The coding sequence for amino acids 1 to 90 of ERh was amplified by PCR of plasmid hERh0 (45) and inserted into pM vector, digested with EcoRI and SalI. MCF-7 cells were cotransfected with combinations of bait and target plasmids, the reporter plasmid and pSV-h-galactosidase plasmid (Promega) as previously described (2, 10) . Cells were cultured for 48 h and then harvested and CAT (liquid scintillation method) and hgalactosidase activities were assayed in whole cell extracts using assay kits (Promega) according to the manufacturer's protocols. CAT activity results were normalized relative to the h-galactosidase activity and are expressed as a percentage of the positive control level (pM-53 + pVP16T). Results are the mean F SD of at least three separate experiments.
Immunoprecipitation and Western Blot for BTFb and ERa
MCF-7 cells were transfected either with an expression plasmid encoding full-length ERa or with the f1 target plasmid encoding BTF3b or with the target plasmid containing the BTF3b cDNA inserted in an antisense orientation (''reversed''). After incubation for 48 h, cells were harvested and whole cell lysates were prepared according to the instructions for immunoprecipitation provided by Santa Cruz Biotechnology. Extracts were mixed and incubated with antibody against BTF3 (Santa Cruz Biotechnology). Immunoprecipitation and Western blot analysis, using antibody against ERa, were carried out according to the instructions of the supplier of the anti-ERa antibody (Santa Cruz Biotechnology). 
Endogenous Immunoprecipitation and Western
In vitro Binding Assay Complex Detection of the Interaction between BTFa and ERa by Coimmunoprecipitation
For immunoprecipitation in vitro, products were generated in a coupled transcription-translation cell-free proteinsynthesizing reticulocyte lysate with [ 35 S]methionine and the expression vector for BTF3a or nonradioactive amino acids and expression vectors for ERa, Tip60-HA, unprogrammed lysate for the empty vector pCMV-HA and immunoprecipitated with monoclonal antibodies to ERa, as well as hemagglutinin antibody as described previously (46) . Characterization of the monoclonal antibody to ERa has been previously undertaken (2) . The rabbit polyclonal antibody to hemagglutinin-tag raised against an internal region of the influenza hemagglutinin protein (sc-805) also produced the correct-sized proteins on Western blots (Santa Cruz Biotechnology; ref. 45) . In detail, cDNA templates for ERa and BTF3a were prepared using a Hybaid kit and resuspended in RNase-free distilled water. An in vitrocoupled transcription and translation kit (T7/T3-TNT; Promega) was used according to the manufacturer's instructions. After completion of the 90-min reaction, samples were kept on ice. One milliliter of the immunoprecipitation buffer [50 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 0.2 mmol/L Na 3 VO 4 , 0.5% (w/v) NP40, 1 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L DTT, 25 Ag/mL leupeptin, 25 Ag/mL aprotinin, and 25 Ag/mL pepstatin] were added to each sample, mixed, and incubated on ice for 30 min. Twenty microliters of protein A/G agarose, prewashed thrice in immunoprecipitation buffer, were added to each sample and incubated for an additional 4 h at 4jC with rotation to remove any proteins that had interacted nonspecifically with protein A/G agarose. Protein A/G agarose was removed by centrifugation at 14,000 rpm for 3 min in a bench-top centrifuge. The supernatant containing [ 35 S]BTF3a was mixed, in turn with supernatants containing nonradioactive ERa, and the combined supernatants were then incubated with 2.5 Ag of the requisite antibody overnight at 4jC with rotation. Twenty microliters of protein A/G agarose were added to each sample and incubated at 4jC for an additional 60 min. Protein A/G agarose antibody conjugates were recovered by centrifugation at 14,000 rpm for 3 min, resuspended in 1 mL of buffer A [PBS, 0.2% (w/v) Triton X-100, and 350 mmol/L NaCl], and recentrifuged. Samples were resuspended in 1 mL of buffer B [PBS, 0.2% (w/v) Triton X-100], centrifuged, and resuspended in SDS sample buffer. Samples were resolved by electrophoresis on 10% (w/v) polyacrylamide gels at 200 V for 45 min with equal amounts of protein being loaded per lane. The gel was fixed for 30 min in 10% (v/v) propanol, 10% (v/v) acetic acid, dried under vacuum, and exposed to Kodak X-Omat AR X-ray film for 6 to 24 h before developing the film as we have previously described (45) .
Northern Blots
Total RNA was extracted from cells and subjected to Northern blot analysis, as previously described (38, 47) . The membranes were hybridized separately and in turn to pBDGAL4 f1, human a-actin, and glyceraldehyde-3-phosphate dehydrogenase probes and subjected to autoradiography.
Transient Transfection of Mammalian Cells
The cDNA insert in the pAD-GAL4 f1 plasmid was released by digestion with EcoRI and SalI and ligated with the mammalian expression vector pBK-CMV (Stratagene), digested with the same two enzymes. MCF-7 and HeLa cells were cotransfected with expression and reporter plasmids as previously described (2, 10, 48) . Cells were incubated for 24 h without any additions or in the presence of hormones (17h-estradiol, 10 nmol/L, or EGF, 100 ng/mL) and were then harvested and CAT and h-galactosidase activities were assayed as previously described (10) . CAT activity results were normalized relative to the h-galactosidase activity, and are expressed as a percentage of the estradiol-induced level, as indicated. Results are the mean F SD of at least three separate experiments.
Western Blot
Western blots were done on whole-cell extracts of transfected cells, using monoclonal antibodies specific for the amino-terminal or carboxyl-terminal domains of human ERa (Santa Cruz Biotechnology) to confirm that the mutated versions of ERa were each expressed at a level equivalent to that of the wild-type receptor.
Statistical Treatment of Results
All experiments were done at least thrice. The mean and SD were calculated for each set of results and the significance of the difference between values was assessed by Student's t test.
